Orenitram is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise capacity in cases of pulmonary arterial hypertension (PAH). Orenitram may be referred to by its drug name, treprostinil.
Orenitram is a prostaglandin. Prostaglandins are hormone-like compounds made by the body. In cases of PAH, lower levels of prostaglandins are associated with narrowing of blood vessels in the lungs. Prostaglandins are believed to work in two ways. First, prostaglandins dilate the blood vessels of the lungs, increasing the blood flow and the amount of oxygen the cells receive. Second, prostaglandins help slow scarring in the blood vessels of the lungs, delaying the progress of the disease.
How do I take it?
Prescribing information states that Orenitram is taken orally two or three times a day.
Orenitram comes in the form of extended-release tablets.
The FDA-approved label for Orenitram lists common side effects including headache, flushed skin, nausea, and diarrhea.
Rare but serious side effects listed for Orenitram include an increased risk for bleeding.
For more details about this treatment, visit:
Orenitram — United Therapeutics
Orenitram (Treprostinil) For Pulmonary Hypertension — Pulmonary Hypertension News